Inventiva S.A. — Form 6-K Summary
Business Context and Reporting Period
Inventiva S.A., a French biopharmaceutical company, furnished this Form 6-K for April 2023. The report was signed and submitted on April 17, 2023.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
The filing reports no financial or operational change versus a prior comparable period. Its purpose is to furnish notice of an upcoming shareholder meeting.
Guidance, Outlook, Risks, and Unusual Items
- Inventiva published a notice for its Ordinary and Extraordinary General Meeting.
- The meeting is scheduled for May 25, 2023, at 2:00 p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon, France.
- The notice is furnished as Exhibit 99.1.
- The filing provides no guidance, management outlook, risk update, contingencies, or unusual financial items.
Investor Verification Points
- Review Exhibit 99.1 for the meeting agenda, proposed resolutions, and voting procedures.
- Verify the May 25, 2023 meeting date, time, and location.
- Consult Inventiva’s applicable annual report or other financial filings for current financial results, liquidity, debt, and operating risks.